TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Propranolol
PubChem CID 4946
Molecular Weight 259.34g/mol
Synonyms

propranolol, Propanolol, 525-66-6, beta-Propranolol, Betalong, Euprovasin, Proprasylyt, Reducor, Propanalol, Anapriline, Propanix, propranololo, Corpendol, Sawatal, dl-propranolol, Sumial, Inderal, Racemic propranolol, Propranololum, D,L-Propranolol, (+-)-Propranolol, racemic-Propranolol, .beta.-Propranolol, 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol, CCRIS 3082, 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, Propanolol [INN-Spanish], UNII-9Y8NXQ24VQ, Propranololum [INN-Latin], EINECS 208-378-0, EINECS 235-867-6, 9Y8NXQ24VQ, hemangiol, 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol, Bedranol, CHEBI:8499, 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+/-)-propranolol, 1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol, 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, CHEMBL27, rac-Propanolol, AY-64043-, Betadren, DTXSID6023525, 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, (+-)-, 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, Inderex, Inderol, Pranolol, Propranolol (INN), (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol, 13013-17-7, 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol, 1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol, PROPRANOLOL [INN], 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-, Inderal hydrochloride, Propanolol (INN-Spanish), Propranololum (INN-Latin), Propranololo [DCIT], 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol, Propranalol, Propranolol [INN:BAN], AY 20694, b-Propranolol, Propranolol (TN), Dociton (Salt/Mix), Inderal (Salt/Mix), Obsidan (Salt/Mix), Propanolol,(+/-), PROPRANOLOL, d, Avlocardyl (Salt/Mix), beta-Propranolol;Dociton, PROPANOLOL(-), PROPRANOLOL [MI], Prestwick0_000952, Prestwick1_000952, Prestwick2_000952, Prestwick3_000952, PROPRANOLOL,(+), PROPRANOLOL,(-), Spectrum2_001301, Spectrum2_001699, Spectrum3_000883, Spectrum3_001071, Spectrum4_000974, Spectrum4_001222, Spectrum5_000751, (.+/-.)-Propranolol, PROPRANOLOL [VANDF], SCHEMBL3955, 3-[(methylethyl)amino]-1-naphthyloxypropan-2-ol, Lopac0_000896, Oprea1_304193, BSPBio_000944, BSPBio_002682, CBDivE_006180, GTPL564, KBioGR_001347, KBioGR_001684, KBioGR_002515, KBioSS_002523, PROPRANOLOL [WHO-DD], DivK1c_000023, SPBio_001361, SPBio_001658, SPBio_003093, (+)-Propranolol hydrochloride; (R)-(+)-Propranolol hydrochloride, 1-(Isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol, BPBio1_001040, DTXCID903525, ICI 45520 (Salt/Mix), NSC 91523 (Salt/Mix), SCHEMBL12264958, BDBM25761, HY-B0573B, KBio1_000023, KBio2_002515, KBio2_005083, KBio2_007651, KBio3_001766, KBio3_001902, KBio3_002993, C07AA05, cMAP_000071, NINDS_000023, (A+/-)-Propranolol hydrochloride, [2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine, Bio1_000367, Bio1_000856, Bio1_001345, HMS2090L21, HMS3428G03, BCP26001, BCP31343, BBL023437, PDSP1_000767, PDSP1_001607, PDSP1_001608, PDSP2_000755, PDSP2_001591, PDSP2_001592, STK735510, AKOS000588816, AKOS016050338, CCG-103643, DB00571, FE-0204, SDCCGSBI-0050871.P004, IDI1_000023, NCGC00015798-04, NCGC00015798-05, NCGC00015798-06, NCGC00015798-07, NCGC00015798-08, NCGC00015798-09, NCGC00015798-15, NCGC00015798-19, NCGC00024690-02, NCGC00024690-03, SBI-0050871.P003, AB00053537, CS-0069968, NS00000196, EN300-40731, C07407, D08443, G60902, AB00053537-10, AB00053537_11, AB00053537_12, 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol, L000679, Q423364, 1(-alpha-naphthoxy)-3-(iso-propylamino)-2-propanol, 1-(alpha-naphthoxy)-3-(iso-propylamino)-2-propanol, 1-(alpha-naphthoxy)-3-(isopropylamino)-2-propanol, 1-isopropylamino-3-(naphthalen-1-yloxy)propan-2-ol, W-109550, 1-(isopropylamino)-3-naphthalen-1-yloxy-propan-2-ol, BRD-A10070317-003-06-9, BRD-A10070317-003-17-6, 1-((1-Methylethyl)amino)-3-(1-naphthyloxy)-2-propanol, 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane, F0001-3681, 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol

Drug Type Small molecule
Formula C₁₆H₂₁NO₂
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
InChI 1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChIKey AQHHHDLHHXJYJD-UHFFFAOYSA-N
CAS Number 525-66-6
ChEMBL ID CHEMBL27
ChEBI ID CHEBI:8499
TTD ID D04JEE
Drug Bank ID DB00571
KEGG ID C07407
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 754
Pair Name Thymoquinone, Propranolol
Partner Name Thymoquinone
Disease Info [ICD-11: 2C23.Z] Laryngeal cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CASP3 hsa836
Down-regulation Expression CCND1 hsa595
Up-regulation Expression TP53 hsa7157
Up-regulation Expression VEGFA hsa7422
In Vitro Model Hep-G2 Hepatoblastoma Homo sapiens (Human) CVCL_0027
Result The effect of thymoquinone and propranolol combination on epidermoid laryngeal carcinoma cell.
03. Reference
No. Title Href
1 The effect of thymoquinone and propranolol combination on epidermoid laryngeal carcinoma cell. Eur Arch Otorhinolaryngol. 2023 Jun;280(6):2849-2858. doi: 10.1007/s00405-023-07825-0. Click
It has been 26283 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP